Tier 2 — strong

Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin

Antonella Riva, Massimo Ronchi, Giovanna Petrangolini, Stefania Bosisio, Pietro Allegrini
European journal of drug metabolism and pharmacokinetics 2019 44(2):169-177

Bibliography

PubMed
PMID 30328058
PubMed Central
PMC6418071
DOI
10.1007/s13318-018-0517-3
Funding
Reported funding/support: We did not receive any specific grant for this research from funding agencies in the public or not-for-profit sectors. The study was funded by Indena SpA.
Competing interests
Reported disclosure: The authors Antonella Riva, Massimo Ronchi, Giovanna Petrangolini, Stefania Bosisio, and Pietro Allegrini are employees of Indena SpA. ETHICAL APPROVAL: All procedures in this study are in accordance with the 1964 Helsinki Declaration (and its amendments) and the criteria of the ethics committee that approved the study. INFORMED CONSENT: Written informed consent, as reviewed by the ethics committee, was obtained individually from all subjects who participated in the study.

Study snapshot

DesignRandomized fasting crossover pharmacokinetic trial
ModelHuman intervention research
Sample12 healthy volunteers
InterventionUnformulated quercetin versus two doses of lecithin-based Quercetin Phytosome
DurationSingle-dose periods; blood sampling through 24 hours
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2019, this source examined forms, absorption and food sources. Design: Randomized fasting crossover pharmacokinetic trial. Sample/model: 12 healthy volunteers. The exposure or intervention was Unformulated quercetin versus two doses of lecithin-based Quercetin Phytosome. Follow-up or treatment period: Single-dose periods; blood sampling through 24 hours.

The lecithin formulation increased measured quercetin exposure and peak concentration compared with unformulated quercetin.

Small acute absorption trial. Exposure differences do not demonstrate superior clinical efficacy or interchangeable milligram doses.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The lecithin formulation increased measured quercetin exposure and peak concentration compared with unformulated quercetin.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Unformulated quercetin versus two doses of lecithin-based Quercetin Phytosome; Single-dose periods; blood sampling through 24 hours.

What this study can and cannot tell us

  • Small acute absorption trial. Exposure differences do not demonstrate superior clinical efficacy or interchangeable milligram doses.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology